09-11-2009: Lab901 Limited has successfully raised £2.4 million in equity funding. This latest vote of confidence comes from Lab901's strong consortium of UK investors, comprising Archangel Informal Investment Ltd, Alliance Trust Equity Partners (ATEP), Scottish Enterprise SVF, Foresight 3 VCT plc and TriCapital Ltd.
Lab901 will use the cash injection to expand international sales of its ScreenTape® laboratory analysis platform and further develop its product range. Since launching in 2007, ScreenTape is now sold in more than 20 countries - including S. Korea, S. Africa, Canada, Venezuela , Malaysia and Mexico as well as many European countries - through a network of 16 distribution partners.
Commenting on the latest round of funding, Joel Fearnley, CEO and co-founder of Lab901, said: "Lab901 has an enviable track record with the successful development and commercialisation of the innovative ScreenTape platform and our existing investors have provided the finance we need to support planned global sales growth."
Lab901 announced that it has been awarded ISO 9001:2008 accreditation for manufacturing quality covering its ScreenTape® System for automated gel electrophoresis. ISO 9001:2008 addresses quality management systems and looks at, among other things, what an organisation does to fulfil a custo ... more
Lab901 and Biofortuna announced that they will collaborate on the launch of an automated PCR Dx system for the rapid detection of certain HLA-related diseases such as coeliac disease. Lab901 will be optimising its automated ScreenTape® PCR diagnostics platform for use with Biofortuna’s ran ... more
Lab901 Limited has successfully raised £2.4 million in equity funding. This latest vote of confidence comes from Lab901's strong consortium of UK investors, comprising Archangel Informal Investment Ltd, Alliance Trust Equity Partners (ATEP), Scottish Enterprise SVF, Foresight 3 VCT plc and ... more